Cart
sales@molnova.com
BLU-945
CAS No. 2660250-10-0
BLU-945( —— )
Catalog No. M37656 CAS No. 2660250-10-0
BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 255 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 117 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 368 | In Stock |
|
| 100MG | 576 | In Stock |
|
| 200MG | 816 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBLU-945
-
NoteResearch use only, not for human use.
-
Brief DescriptionBLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).
-
DescriptionBLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
-
In Vitro——
-
In VivoAnimal Model:triple-mutant osimertinib-resistant Ba/F3 CDX and PDCX models Dosage:0-100 mg/kg Administration:oral, twice daily Result:Showed significant tumor regression in an osimertinib-resistant EGFR ex19del/T790M/C797S PDCX.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2660250-10-0
-
Formula Weight556.7
-
Molecular FormulaC28H37FN6O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (179.63 mM; Ultrasonic )
-
SMILESCO[C@@H]1CCN(C[C@@H]1F)c1nccc(Nc2cc3c(ccc(N4C[C@H](CS(C)(=O)=O)[C@H]4C)c3cn2)C(C)C)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1.
molnova catalog
related products
-
Monastrol
Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5.
-
Dacomitinib
Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively.
-
WHI-P154
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
